Individualizing treatment of refractory and relapsed ITP in adults and its development of study.
- Author:
Yu HUANG
1
,
2
;
Wei LI
;
Bo YANG
;
Hong-Li ZHU
;
Yan-Hui DANG
Author Information
1. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China
2. Tumor Center of the First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Humans;
Precision Medicine;
methods;
Purpura, Thrombocytopenic, Idiopathic;
therapy;
Recurrence
- From:
Journal of Experimental Hematology
2009;17(6):1609-1615
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic thrombocytopenic purpura (ITP) is a common hematological disease. It bleeds with peripheral blood platelet reduction as the main clinical manifestation, and manifests a chronic history in adult people. 11% - 35% ITP patients develop into a refractory course, which may be related with gene polymorphisms. There is currently no consensus on how best to manage refractory/relapsed ITP. In part, this reflects the need for individualized treatment due to the patients' requirements and their responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article summarizes all the treatment for refractory ITP, and highlights new therapies, including the anti-CD20 antibody, thrombopoietic agents, TPO receptor agonist and HSCT. The pancytoprotector shows good effect in the treatment of refractory and relapsed ITP in China. In a word, to give different treatments individually is most important.
